MX380367B - Metodo para reducir o inactivar contenido viral o microbiano en los procesos para la fabricacion de pancreatina. - Google Patents

Metodo para reducir o inactivar contenido viral o microbiano en los procesos para la fabricacion de pancreatina.

Info

Publication number
MX380367B
MX380367B MX2017014743A MX2017014743A MX380367B MX 380367 B MX380367 B MX 380367B MX 2017014743 A MX2017014743 A MX 2017014743A MX 2017014743 A MX2017014743 A MX 2017014743A MX 380367 B MX380367 B MX 380367B
Authority
MX
Mexico
Prior art keywords
pancreatin
reducing
microbial content
manufacturing processes
inactivating viral
Prior art date
Application number
MX2017014743A
Other languages
English (en)
Other versions
MX2017014743A (es
Inventor
Anisha Akula
Carmen Fritz
Colin Crowley
Dana Spangenberg
Dustin Nielsen
Jon Restivo
Karla Anhalt
Kenneth S Manning
Mark Romich
Ryan Ruf
Yan Wang
Original Assignee
Scient Protein Laboratories Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scient Protein Laboratories Llc filed Critical Scient Protein Laboratories Llc
Publication of MX2017014743A publication Critical patent/MX2017014743A/es
Publication of MX380367B publication Critical patent/MX380367B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/94—Pancreatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10061—Methods of inactivation or attenuation
    • C12N2750/10063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14361—Methods of inactivation or attenuation
    • C12N2750/14363—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32211—Cardiovirus, e.g. encephalomyocarditis virus
    • C12N2770/32261—Methods of inactivation or attenuation
    • C12N2770/32263—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un método para la reducción inactivación del contenido viral y microbiano en la fabricación del ingrediente farmacéutico activo pancreatina. El método incluye tratar tejido derivado de animal con ácido peracético para reducir la actividad viral y la carga bacteriana antes del procesamiento. En particular, el método incluye tratar páncreas porcino con ácido peracético antes de extraer un ingrediente farmacéutico activo pancreatina del tejido glandular tratado.
MX2017014743A 2015-05-19 2016-05-19 Metodo para reducir o inactivar contenido viral o microbiano en los procesos para la fabricacion de pancreatina. MX380367B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562163779P 2015-05-19 2015-05-19
PCT/US2016/033329 WO2016187455A1 (en) 2015-05-19 2016-05-19 Method for reducing or inactivating viral and microbial content in the processes for the manufacture of pancreatin
US15/159,345 US10093916B2 (en) 2015-05-19 2016-05-19 Method for reducing or inactivating viral and microbial content in the processes for the manufacture of pancreatin

Publications (2)

Publication Number Publication Date
MX2017014743A MX2017014743A (es) 2018-01-26
MX380367B true MX380367B (es) 2025-03-12

Family

ID=57320830

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014743A MX380367B (es) 2015-05-19 2016-05-19 Metodo para reducir o inactivar contenido viral o microbiano en los procesos para la fabricacion de pancreatina.

Country Status (7)

Country Link
US (2) US10093916B2 (es)
EP (1) EP3298139B1 (es)
CN (2) CN107849552B (es)
CY (1) CY1124679T1 (es)
MX (1) MX380367B (es)
PL (1) PL3298139T3 (es)
WO (1) WO2016187455A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3298139T3 (pl) * 2015-05-19 2022-01-31 Scientific Protein Laboratories Llc Sposób zmniejszenia lub inaktywacji zawartości wirusów i drobnoustrojów w sposobach wytwarzania pankreatyny
CN108795920B (zh) * 2018-06-22 2022-04-08 苏州良辰生物医药科技有限公司 一种胰酶的制备方法
CN109810968B (zh) * 2019-03-13 2021-03-02 淮安麦德森制药有限公司 胰酶的制备方法
CN112708611A (zh) * 2021-01-19 2021-04-27 四川菲德力制药有限公司 一种胰酶制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3956483A (en) 1968-10-24 1976-05-11 Wilson Pharmaceutical & Chemical Corporation Preparing pancreatin
US4986963A (en) 1989-01-24 1991-01-22 Corcoran Richard A Method of disinfecting contact lenses with peracetic acid
US20020192731A1 (en) * 2001-04-12 2002-12-19 H. Shih Jason C. Method and composition for sterilizing surgical instruments
US6749851B2 (en) 2001-08-31 2004-06-15 Clearant, Inc. Methods for sterilizing preparations of digestive enzymes
WO2004037168A2 (en) * 2002-10-18 2004-05-06 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
JP5140586B2 (ja) * 2005-07-29 2013-02-06 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 滅菌パンクレアチン粉末の製法
US20090130063A1 (en) 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
WO2009063065A1 (en) * 2007-11-15 2009-05-22 Solvay Pharmaceuticals Gmbh Novel process for separating and determining the viral load in a pancreatin sample
EP2165717A1 (de) 2008-08-27 2010-03-24 Nordmark Arzneimittel GmbH & Co.KG Verfahren zur Verringerung der viralen und mikrobiellen Belastung feststoffhaltiger biologischer Extrakte
ATE541591T1 (de) 2008-11-03 2012-02-15 Nordmark Arzneimittel Gmbh & Co Kg Verfahren zur verringerung der viralen und mikrobiellen belastung von pankreatin
RU2012106760A (ru) * 2009-07-21 2013-08-27 Трансген Са Ферментативная композиция для ферментативного расщепления куриного эмбриона
US9511125B2 (en) * 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
KR102081356B1 (ko) 2009-11-12 2020-02-25 브이셀 세라퓨틱스 인코포레이티드 포자를 닮은 세포들의 계군 및 그 용도
KR20130062905A (ko) 2010-03-19 2013-06-13 앱탈리스 파마 캐나다 아이엔씨. 췌장 효소 약학 제제에서 바이러스를 불활성화하는 베타-프로피오락톤
PL3298139T3 (pl) * 2015-05-19 2022-01-31 Scientific Protein Laboratories Llc Sposób zmniejszenia lub inaktywacji zawartości wirusów i drobnoustrojów w sposobach wytwarzania pankreatyny

Also Published As

Publication number Publication date
US20180362958A1 (en) 2018-12-20
EP3298139A4 (en) 2019-02-06
WO2016187455A1 (en) 2016-11-24
BR112017024920A2 (pt) 2018-07-31
CY1124679T1 (el) 2022-07-22
US11952603B2 (en) 2024-04-09
CN107849552B (zh) 2021-11-02
PL3298139T3 (pl) 2022-01-31
CN113750224B (zh) 2024-04-30
EP3298139A1 (en) 2018-03-28
CN113750224A (zh) 2021-12-07
US20170037392A1 (en) 2017-02-09
MX2017014743A (es) 2018-01-26
CN107849552A (zh) 2018-03-27
EP3298139B1 (en) 2021-09-15
US10093916B2 (en) 2018-10-09

Similar Documents

Publication Publication Date Title
CY1124679T1 (el) Μεθοδος μειωσης η απενεργοποιησης του ιικου και μικροβιακου περιεχομενου στις μεθοδους παρασκευης παγκρεατινης
MX2021010528A (es) Metodos y composiciones para el tratamiento de las ulceras.
EA201991556A1 (ru) Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции
BR112015013123A2 (pt) inibidores de beta-lactamase
MX384240B (es) Bacterias probioticas recombinantes.
EA202191067A1 (ru) Композиции и способы для лечения дефицита альфа-1-антитрипсина
EA201890728A2 (ru) Лечение ингибиторами ntcp атеросклероза, первичного билиарного цирроза и заболевания, связанного с nrlp3-инфламмасомами
EP3530124A4 (en) DIET CONTAINING A SUBTILUS BACILIUS STRAIN, BACILIUS PUMILUS STRAIN AND BACILIUS LICHENFORMIS STRAIN AS ACTIVE INGREDIENTS FOR PREVENTING OR TREATING ACUTE HEPATOPANCREATIC NECROSIS DISEASE OR BLANCHANCHESIS SYNDROME
UY36332A (es) Composiciones de bacillus pumilus rt1279 y metodos de uso para benefficiar el crecimiento de las plantas
PH12017501300A1 (en) Novel iodophor composition and methods of use
EP4368210A3 (en) Virus inactivation method
ZA202006612B (en) Antibacterial compounds
EA201591424A1 (ru) Способы лечения дефицита железа растворимым пирофосфатом железа
MX2019000235A (es) Eliminacion de la cistina mediada por enzimas humanas.
MX386601B (es) Disminución de homocisteína mediada por enzimas humanas para el tratamiento de pacientes con hiperhomocisteinemia y homocistinuria.
EA201791051A1 (ru) Способ лечения, профилактики или снижения риска возникновения кожной инфекции
MX2019002405A (es) Desactivacion de patogenos en medios biologicos.
WO2013162981A3 (en) Breast implant spacers for the treatment of periprosthetic breast implant infections
AR125341A2 (es) Conservante de heno y métodos de conservación del heno
MX2023004881A (es) Inhibidores de pde9 para el tratamiento de insuficiencia cardíaca.
EA201992210A1 (ru) Предотвращение и/или лечение воспалительного заболевания кожи
GB2571493A (en) Methods and products for reducing resistance to anti-parasitic agents
EA202192668A1 (ru) Способ и композиция для терапевтического лечения непереносимости глютена
PH12015502092A1 (en) Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
PL409283A1 (pl) Enzym o wysokiej aktywności litycznej w stosunku do komórek Enterococcus oraz sposób modyfikacji jego genu pozwalający na nadprodukcję aktywnego enzymu w komórkach bakteryjnych